Name: FDA Catalyst: Example Drug
Start: 2026

Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Cerus Corporation

$3.12

-0.03 (-0.95%)

C 47Pipeline Score MedTech · Commercial

Market Cap

543.00 M

EPS

-0.05

P/E Ratio

Value Trade

5.83 M

SEC Financials

Q1 2026

Dilution Risk
5%
Revenue
53.66 M
R&D Expenses
14.53 M
Operating CF
-3.05 M

Total Assets
222.91 M
Total Liabilities
154.62 M
Equity
67.55 M
D/E Ratio
12,345

8.84 %

Week

40.41 %

1 Month

6.69 %

3 Month

83.11 %

6 Month

-54.38 %

5 Year

-77.88 %

All Time

Cash Data

Healthy

Cash Position
80.43 M
Monthly Burn
1.02 M
Runway
77.1 mo
Burn Trend
Accelerating
SEC Filing
Apr 30, 2026

Overview

Volume

1.73 M

52 Week Range

1.15 - 3.15

% held by Insiders

5.44 %

% held by Institutions

73.71 %

Enterprise Value

560.67 M

Total Shares

200.41 M

Short %

6.68 %

Float Shares

190.79 M

Company Description

HQ: 1220 CONCORD AVENUE, CONCORD, ...

Employees:345

https://www.cerus.com

locked

Upcoming Catalyst

Catalyst	Drug/Treatment	Stage	Probability of Approval	Description	Drug Type	Therapeutic Area
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology

Unlock Upcoming Catalyst data

Drug Pipeline Intelligence

C47

Pipeline Score

$688M

Pipeline Value

Valuation Signal

Drugs Scored

1.3x

rNPV / MCap

Top 71%

Micro Cap

(rank 265 of 911)

Percentile Rank

Cerus Corporation carries a moderate pipeline score (47/100), with $1.7B risk-adjusted pipeline value, led by S-303 Red Blood Cells - Test in Focus:Use of S303 RBCs in Patients With Acute Anemia (Phase 3).

Showing 1 of 1 assets

Drug	Indication	Phase	NCT ID	PTRS	rNPV	Status	Enrollment	Velocity	Design	Completion	ML Signal	Last Change
S-303 Red Blood Cells - Test Monoclonal antibody	Focus:Use of S303 RBCs in Patients With Acute Anemia	Phase 3	NCT01716923	79%	$1.2B	COMPLETED	81	-	-	Oct 1, 2014	-	Aug 26, 2015

Unlock Drug Pipeline Intelligence

Clinical Trial Results

Drug Name	Indications	Phase	Date	Trial Results Summary	Title
INTERCEPT RBC system	RBC transfusion for complex cardiac surgery patients	Phase 3	2024-10-16	positive topline results for the BARDA-funded ReCePI study, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs when transfused to complex cardiac surgery patients Read More	Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe Company to Host Conference Call and Webcast on Wednesday Read More
INTERCEPT RBC system	RBC transfusion for complex cardiac surgery patients	Phase 3	2024-10-16	positive topline results for the BARDA-funded ReCePI study, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs when transfused to complex cardiac surgery patients Read More	Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe Company to Host Conference Call and Webcast on Wednesday Read More
INTERCEPT RBC system	RBC transfusion for complex cardiac surgery patients	Phase 3	2024-10-16	positive topline results for the BARDA-funded ReCePI study, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs when transfused to complex cardiac surgery patients Read More	Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe Company to Host Conference Call and Webcast on Wednesday Read More

Unlock Clinical Trial Results data

Inside Trades

YEARLY INSIDER TRANSACTIONS

Sector Avg.

INSIDERS
SOLDINSIDERS
BOUGHT

POSITIVE SENTIMENT Based on 22 Insiders Transactions

Unlock Inside Trades data

Show Data

Hedge Funds

Shares Held

2040.00B1530.00B1020.00B510.00B0

Q3
2024

Q4
2024

Q1
2025

Q2
2025

HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT

POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter

18 buying (3 new)·9 selling (1 exited)·2 unchanged

Fund Count

60%

Share Volume

25%

Conviction

15%

Hedge Funds invested in CERS

HedgeFund Name ( 3 )	% of Portfolio	Current MV -	Shares Owned -
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K

Unlock Hedge Funds table data

CERS Institutional Ownership Trends

Current Insider %

5.20%

—+0.00%

Current Institutional %

62.40%

—+0.00%

Total Ownership

67.60%

Insider + Institutional

Data Points

1 Ticker(s)

Option Chain Statistics

Expiration	Volume			Open Interest			Implied Volatility Calls			Implied Volatility Puts
Expiration	Calls	Puts	Put-Call Ratio	Calls	Puts	Put-Call Ratio	IV	OiWaIv	VWaIv	IV	OiWaIv	VWaIv
2026-08-21			0.00			0	-	-	-	-	-	-
2026-08-21			0.00			0	-	-	-	-	-	-
2026-08-21			0.00			0	-	-	-	-	-	-

Unlock Option Chain Statistics data

Option Chain

Calls			Strike	Puts
Last Price	Volume	Open Interest	Strike	Last Price	Volume	Open Interest
No data available

Unlock Option Chain data

Unlock Options Chart data

Open interest

Today's Open Interest

1.00 M

Put-Call Ratio

1.1

Put Open Interest

480.00 K

Call Open Interest

520.00 K

Open Interest Avg (30-day)

900,000

Today vs Open Interest Avg (30-day)

11.11%

Option Volume

Today's Volume

750.00 K

Put-Call Ratio

0.95

Put Volume

360.00 K

Call Volume

390.00 K

Volume Avg (30-day)

800,000

Today vs Volume Avg (30-day)

-6.25%

a16z generative ai

Hippocratic AI has secured $141 million in Series B funding to develop AI agents aimed at improving healthcare delivery. The startup focuses on creating specialized AI tools for clinicians to enhance patient care, while also integrating blockchain technology to protect intellectual property. The funding will accelerate product development and expand their team.

CERS

Jul 2, 2026

CERSGeneral

▲ +5.3%on this newsshared move

JFK School Healthcare facility

Hackensack Meridian Health is a prominent not-for-profit healthcare organization in New Jersey, operating 17 hospitals and over 500 care centers. The facility focuses on providing comprehensive medical services, including innovative research and patient care. They emphasize community support and the integration of various healthcare professionals to enhance patient outcomes.

CERS

Jun 25, 2026

CERSGeneral

best name for dog 25

The upcoming animated film 'The Cat in the Hat' is set to release on November 6, 2026. Directed by Alessandro Carloni, it features a talented voice cast and aims to modernize the classic Dr. Seuss story. The film is part of a new shared universe called the Seussiverse, promising an exciting cinematic experience for families.

CERS

Jun 25, 2026

CERSGeneral

best name for dog 24

The article discusses popular dog names for 2024, highlighting unique options for both male and female dogs. It emphasizes the importance of personal choice and the emotional connection between pet owners and their dogs. Additionally, it provides insights into naming trends based on breed and geographical location, encouraging readers to explore various naming options.

CERS

Jun 25, 2026

CERSGeneral

▲ +8.3%on this newsshared move

Глоссарий Форекс: объяснение ключевых торговых терминов для начинающих

The article provides an overview of key forex trading terms for beginners. It explains concepts such as soft currency, bid prices, and various types of orders like buy stop and buy limit. Additionally, it discusses the importance of understanding market dynamics and trading strategies. The content aims to assist novice traders in navigating the forex market effectively.

CERS

Jun 17, 2026

CERSConferences/Events

Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress

Cerus Corporation will present new evidence and innovations related to the INTERCEPT Blood System at the 39th International ISBT Congress. The event will highlight the company's global experience in blood safety and pathogen reduction technologies. Details on specific findings or innovations to be showcased were not provided.

CERS

Jun 8, 2026

CERSGeneral

Cerus Corporation Closes New Debt Facility of Up to $110 Million

Cerus Corporation has successfully closed a new debt facility that allows for borrowing up to $110 million. This financial move is aimed at strengthening the company's capital structure. Further details on the terms of the facility and its intended use were not disclosed in the announcement.

CERS

Apr 30, 2026

CERSGeneral

▲ +5.7%on this news· ran to +42% by day 1

Cerus Corporation Announces First Quarter 2026 Financial Results

Cerus Corporation reported a strong start to 2026, with first-quarter revenues of $59.9 million, marking a 23% increase from the previous year. The company raised its product revenue guidance for the year, driven by heightened demand for its INTERCEPT Fibrinogen Complex. Despite a net loss of $1.6 million, Cerus anticipates significant regulatory and clinical milestones ahead.

CERS

Apr 27, 2026

CERSGeneral

Cerus Corporation will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The event will feature a live webcast accessible via the company's Investor Relations page. Cerus is focused on safeguarding the blood supply and has developed the INTERCEPT Blood System, which is approved in various regions.

CERS

Feb 18, 2026

CERSConferences/Events

Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026

Cerus Corporation announced that it will release its fourth quarter and full-year 2025 financial results on March 2, 2026. Following the release, a conference call and webcast will be held at 4:30 P.M. ET to discuss the results and provide a business overview. The company is dedicated to ensuring the safety of the blood supply through its innovative technologies.

CERS

Jan 22, 2026

CERSPhases

DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT™ Blood System in Routine Clinical Practice

Cerus Corporation has announced the launch of the INITIATE study in collaboration with the German Red Cross Blood Donation Service Baden-Württemberg – Hessen. This multicenter, non-interventional study will evaluate the safety and integration of pathogen-inactivated platelet concentrates using the INTERCEPT Blood System in clinical practice. The study aims to enhance blood safety and ensure a reliable supply of platelets.

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update Preliminary Full-Year 2024 Product Revenues Total $180.3 million, 15% Over 2023 Results and Exceed Pr

Cerus Corporation announced preliminary product revenues for 2024, totaling $180.3 million, representing a 15% increase over 2023 results. The company also projected 2025 product revenues between $194 and $200 million, reflecting ongoing growth driven by its INTERCEPT platelet franchise. While optimism surrounds the revenue progression, challenges such as market acceptance and reliance on external factors persist. Complete financial results for 2024 will be disclosed later this quarter.

CERS

Oct 30, 2024

CERSGeneral

Cerus Corporation Announces Third Quarter 2024 Financial Results Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods Raising Full-Year 2024 Total Product Revenue

Cerus Corporation announced its financial results for Q3 2024, showing a significant increase in product revenue of 16% compared to the previous year. The company has raised its full-year revenue guidance based on strong performance and growth expectations. Key highlights include a new six-year contract with BARDA valued at up to $248 million and continued developments in the INTERCEPT product pipeline, despite a decline in government contract revenues. The company's net loss decreased significantly, with positive adjusted EBITDA reported for the quarter.

CERS

Oct 16, 2024

CERSPhases

Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe Company to Host Conference Call and Webcast on Wednesday

Cerus Corporation announced updates on its INTERCEPT red blood cell programs, highlighting a new $248 million contract with BARDA to support development efforts in the U.S. The company reported positive results from the ReCePI Phase 3 trial and is actively enrolling patients in the RedeS trial. However, they faced setbacks in Europe as their CE Mark application was not approved due to insufficient data regarding the product's impurity profile. Cerus remains optimistic about addressing these issues in future submissions.

CERS

Aug 1, 2024

CERSGeneral

▼ -9.7%on this news

Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2

Cerus Corporation reported financial results for the second quarter of 2024, showcasing a 20% increase in product revenue compared to the previous year. The company raised its full-year product revenue guidance from $172-175 million to $175-178 million, reflecting confidence in increasing market demand. Key highlights included achieving 100% adoption of INTERCEPT platelets by Canadian Blood Services. Despite a net loss of $5.8 million, the company recorded positive operating cash flows for the second straight quarter.

CERS

Jul 2, 2024

CERSGeneral

Cerus Corporation reported financial results for Q3 2023, achieving a total revenue of $47.3 million, driven by product revenue of $39.8 million and government contract revenue of $7.5 million. The company completed enrollment for its Phase 3 ReCePI study, with top-line data expected in Q1 2024. Cerus also indicated a strategic push toward achieving breakeven non-GAAP adjusted EBITDA by Q4 2023, while noting an increase in cash used in operations. Despite a reduced net loss year-over-year, challenges remain as the company adjusts revenue guidance due to a recent sales agreement delay.

CERS

Aug 2, 2023

CERSGeneral

Cerus Corporation Announces Second Quarter 2023 Financial Results CONCORD, CA

Cerus Corporation reported its financial results for the second quarter of 2023, achieving total revenue of $47.7 million. The company received positive feedback regarding the CE Mark submission for INTERCEPT Red Blood Cells and secured additional funding from the U.S. Department of Defense. However, it adjusted its full-year revenue guidance downward due to factors including a temporary reduction in U.S. platelet kit shelf life and new sanctions related to Russia. The increase in operating expenses and a larger net loss also indicated ongoing financial challenges.

CERS

May 4, 2023

CERSGeneral

Cerus Corporation Announces First Quarter 2023 Financial Results Reiterating Full-Year 2023 Product Revenue Guidance Range of $165-170 Million CONCORD, CA

Cerus Corporation reported its financial results for Q1 2023, showcasing a total revenue of $38.5 million, a decrease from $43 million in the previous year. The company reaffirmed its full-year product revenue guidance of $165-170 million, citing improvements in customer order patterns. However, product revenue saw a notable decline of 17% due to inventory adjustments. The firm achieved a fifth consecutive quarter of gross margin expansion while also facing increased operational expenses and a net loss of $15.6 million.

CERS

Feb 28, 2023

CERSGeneral

Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results Strong Revenue Growth Driven by Sales in North America Product Revenue of $44.0 Million Grew 10% YoY in the Fourth Quarter Reiteratin

Cerus Corporation reported strong financial results for the fourth quarter and full-year 2022, with product revenue growing by 10% YoY to $44 million. Despite an overall revenue increase, government contract revenue saw a decline. The company remains focused on expanding its INTERCEPT product portfolio and has reiterated its revenue guidance for 2023, anticipating product revenue between $165 and $170 million. Although net losses have increased, Cerus is optimistic about its growth trajectory and the success of its blood safety solutions.

CERS

Jan 9, 2023

CERSGeneral

▼ -28%on this news

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update Preliminary Fourth Quarter and Full-Year 2022 Product Revenues of $44.0 million and $162.0 million re

Cerus Corporation announced preliminary product revenues for Q4 2022 amounting to $44 million, reflecting a 10% growth compared to Q4 2021. For the full year, product revenues reached $162 million, marking a 24% increase from 2021 and topping company forecasts. Despite this positive growth, Cerus anticipates challenges in 2023 due to macroeconomic uncertainties, which could impede broader adoption of its products. The company remains focused on expanding its market reach and sustaining its business momentum.

CERS

Nov 3, 2022

CERSGeneral

Cerus Corporation Announces Third Quarter Financial Results Total Revenue of $46.3 Million Grew 10% YoY in the Third Quarter Product Revenue of $39.6 Million Grew 10% YoY in the Third Quarter despite 6% FX headwind CONCO

Cerus Corporation Announces Third Quarter Financial Results Total Revenue of $46.3 Million Grew 10% YoY in the Third Quarter Product Revenue of $39.6 Million Grew 10% YoY in the Third Quarter despite 6% FX headwind CONCORD, CA, November 3, 2022 - Cerus Corporation (Nasdaq: CER

CERS

Aug 4, 2022

CERSGeneral

Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range Second Quarter 2022 is Highest Product Revenue in Company History Total Revenue of $47.6 Million Grew 26% Yo

Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Second Quarter 2022 is Highest Product Revenue in Company History Total Revenue of $47.6 Million Grew 26% YoY in the Second Quarter Product Revenue of $41.0 Million Grew 3

CERS

Jul 5, 2022

CERSGeneral

Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors CONCORD, CA

Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors CONCORD, CA, July 5, 2022 - Cerus Corporation (Nasdaq: CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Sta

Cerus Corporation Prices Public Offering of Common Stock and Warrants CONCORD, California November 10, 2010 Cerus Corporation (NASDAQ: CERS) today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common s

CERS

Oct 28, 2010

CERSGeneral

Kevin D. Green Jason Spark Vice President, Finance & CAO Canale Communications Cerus Corporation (619) 849-6005 (925) 288-6138

Contact: Kevin D. Green Jason Spark Vice President, Finance & CAO Canale Communications Cerus Corporation (619) 849-6005 (925) 288-6138 CERUS CORPORATION REPORTS THIRD QUARTER RESULTS CONCORD, CA, October 28, 2010 - Cerus Corporation (NASDAQ: CERS) today announced financ

Competitive Position

How CERS ranks across every disease it competes in

Competitive Position is a premium feature

See how CERS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.

Start free trial

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

M&A Tracker

News

Blogs

Modality Leaderboard

API

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

$3.12

SEC Financials

Cash Data

Overview

Company Description

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Hedge Funds

Hedge Funds invested in CERS

CERS Institutional Ownership Trends

Option Chain Statistics

Option Chain

Open interest

Option Volume

Company News

Estructuras_seguras_con_1xslots_para_apuestas_deportivas_y_casino_online_confiab

Posibilidades_únicas_y_felixspin_para_transformar_tu_estrategia_digital_actual

Каким образом сеть воздействует в отношении способность по отношению к вдумчивому взаимодействию

Modernes_Spielen_leicht_gemacht_mit_der_need_for_slots_app_und_ihren_vielfältig

Razkošnost_igralništva_s_vegashero_in_raznolikost_izbire_za_nove_avanture

Απίστευτες_διαδρομές_με_την_winairlines_και_οι_οι

Как можно вывести бонус с бонусного счета 1xbet и применить его?

Beste Wettanbieter ohne OASIS: Ihr Leitfaden für schnelle Auszahlungen und attraktive Boni

Online Casino Conditions Described Without the Common Marketing Noise

Veilig en snel: hoe je betalingen regelt bij Beste Online Casino Zonder Cruks 2026

관심 표명 필수! 클라우드플레어

Obtain Free Spin Bonuses on Slot Machines at Internet Casinos.

Greatest Gambling establishment Incentives & Welcome Offers 2026

Safer Web based casinos Canada: Trusted Real money Sites 2025

Everything You Need To Know About Behavioral Segmentation + Examples

What is Behavioral Segmentation? 6 Effective Strategies & Examples

PayID Casinos for Australian players: top real money pokies and fast withdrawal features

The Founding of YouTube A Short History

Обзор онлайн-казино 1хбет: Скачать на Андроид по прямой ссылке

What Players Say About the Best Online Casino in Canada

Sensible Medical insurance Preparations

Dexsport e a Copa do Mundo 2026: tudo sobre apostas em Espanha vs Bélgica

Apuestas cripto en el Mundial 2026: ¿cómo influye el duelo España vs Bélgica?

Übersicht über Wettanbieter ohne Oasis und Wettlimits

Beste Wettanbieter ohne OASIS: Sichere Fußballwetten mit attraktiven Boni und schnellen

Cazeus Casino: acceso seguro y rápido a tus juegos favoritos en línea

Casea Casino België: ontdek de welkomstbonus en speel met een breed spelaanbod

Explore WekaWin Somalia&#8217;s casino features: live games and unmatched rewards

What to know about betting on DBbet Sri Lanka: a comprehensive overview for players

Snel uitbetalen bij het beste online casino zonder Cruks: wat je moet weten over

أفضل نصائح المراهنة لمباراة سويسرا ضد كولومبيا: كيف تحقق أرباحًا من رهاناتك؟

Argentine vs Égypte : tout savoir sur les paris en direct et les meilleures

Secure your bets with Portugal vs Spain odds: understanding payment methods

Explore the top features of best fast payout casinos Australia: Fast cashouts and immersive

France vs Morocco betting breakdown: expert predictions and payment tips for 2026

Coronavirus disease 2019

Командная динамика: как сотрудничество приводит к совместным победам на Casino X

Изучение возможностей после того, как вы 1win скачали приложение

Explore WekaWin Somalia’s casino features: live games and unmatched rewards

1xbet Nigeria App 2026: Download, Features & Full Review

Découvrez l’application mobile du casino : jeux rapides et accès simplifié